MKI67 and neoplasm: To benchmark against tumor proliferation rate, we first evaluated ROC performance for MKI67+ tumor cell percentage (Supplementary Fig. S8A) and then compared CD8+ T-cell densities and G-cross function values for discriminating cancer-specific survival (Supplementary Fig. S8B).